Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2O.Ti |
Molecular Weight | 79.866 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O--].[O--].[Ti+4]
InChI
InChIKey=SOQBVABWOPYFQZ-UHFFFAOYSA-N
InChI=1S/2O.Ti/q2*-2;+4
DescriptionCurator's Comment: description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_ClinPharmR.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18503414
Curator's Comment: description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_ClinPharmR.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18503414
Titanium dioxide, also known as titanium(IV) oxide or titania, is the naturally occurring oxide of titanium, chemical formula TiO
2. When used as a pigment, it is called titanium white, Pigment White 6 (PW6), or CI 77891. Generally it is sourced from ilmenite, rutile and anatase. It has a wide range of applications, from paint to sunscreen to food coloring. When used as a food coloring, it has E number E171. World production in 2014 exceeded 9 million metric tons. Titanium dioxide has excellent ultraviolet (UV) resistant qualities and acts as a UV absorbent. In the pharmaceutical industry, titanium dioxide is used in most sunscreens to block UVA and UVB rays, similar to zinc oxide. It is also commonly used as pigment for pharmaceutical products such as gelatin capsules, tablet coatings and syrups. In the cosmetics industry, it is used in toothpaste, lipsticks, creams, ointments and powders. It can be used as an opacifier to make pigments opaque. The FDA has approved the safety of titanium dioxide for use as a colorant in food, drugs and cosmetics, including sunscreens. However, controversy exists as to the safety of titanium dioxide nanoparticles used in the cosmetics industry, for example in sunscreens. Titanium and zinc oxides may be made into the nanoparticle size (0.2-100 nanometers) to reduce the white appearance when applied topically, but retain the UV blocking properties. Recent studies suggest titanium dioxide nanoparticles may be toxic, although further research is needed.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18503414
Curator's Comment: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_ClinPharmR.pdf
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: ultraviolet induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/18503257 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | ANTHELIOS 40 Approved UseUnknown Launch Date2008 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Increased expression of manganese-containing superoxide dismutase in rat lungs after inhalation of inflammatory and fibrogenic minerals. | 1994 Mar |
|
Titanium, chromium and cobalt ions modulate the release of bone-associated cytokines by human monocytes/macrophages in vitro. | 1996 Dec |
|
Cytokine and prostaglandin E2 release from leukocytes in response to metal ions derived from different prosthetic materials: an in vitro study. | 1999 Dec |
|
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. | 2001 Feb |
|
Effects of hydroxyapatite particulate debris on the production of cytokines and proteases in human fibroblasts. | 2001 Jul |
|
Matrix metalloproteinases MMP-2, -9 and tissue inhibitors TIMP-1, -2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics. | 2004 Jan 1 |
|
Molecular and biomechanical characterization of mineralized tissue by dental pulp cells on titanium. | 2005 Jun |
|
Chemokine gene activation in human bone marrow-derived osteoblasts following exposure to particulate wear debris. | 2006 Apr |
|
Upregulation of LITAF mRNA expression upon exposure to TiAlV and polyethylene wear particles in THP-1 macrophages. | 2007 Apr |
|
Reconsideration of serum Ti(IV) transport: albumin and transferrin trafficking of Ti(IV) and its complexes. | 2008 Feb 20 |
|
Pulmonary exposure to particles during pregnancy causes increased neonatal asthma susceptibility. | 2008 Jan |
|
Disturbed mitotic progression and genome segregation are involved in cell transformation mediated by nano-TiO2 long-term exposure. | 2009 Dec 1 |
|
Toxicity and penetration of TiO2 nanoparticles in hairless mice and porcine skin after subchronic dermal exposure. | 2009 Dec 1 |
|
Differential binding of inorganic particles to MARCO. | 2009 Jan |
|
Alumina ceramic particles, in comparison with titanium particles, hardly affect the expression of RANK-, TNF-alpha-, and OPG-mRNA in the THP-1 human monocytic cell line. | 2009 Jun |
|
The effects of implant surface nanoscale features on osteoblast-specific gene expression. | 2009 Sep |
|
Inhibitor of differentiation 1 (Id1) expression attenuates the degree of TiO2-induced cytotoxicity in H1299 non-small cell lung cancer cells. | 2009 Sep 28 |
|
Influence of metals on cytokines production in connection with successful implantation therapy in dentistry. | 2010 |
|
Involvement of JNK and P53 activation in G2/M cell cycle arrest and apoptosis induced by titanium dioxide nanoparticles in neuron cells. | 2010 Dec 15 |
|
Airway exposure to silica-coated TiO2 nanoparticles induces pulmonary neutrophilia in mice. | 2010 Feb |
|
Titanium dioxide nanoparticles cause apoptosis in BEAS-2B cells through the caspase 8/t-Bid-independent mitochondrial pathway. | 2010 Jun 16 |
|
Spleen injury and apoptotic pathway in mice caused by titanium dioxide nanoparticules. | 2010 Jun 2 |
|
Titanium ion induces necrosis and sensitivity to lipopolysaccharide in gingival epithelial-like cells. | 2010 Oct |
|
Cellular responses by stable and uniform ultrafine titanium dioxide particles in culture-medium dispersions when secondary particle size was 100 nm or less. | 2010 Sep |
|
Chemoprotective effect of N-acetylcysteine (NAC) on cellular oxidative damages and apoptosis induced by nano titanium dioxide under UVA irradiation. | 2011 Feb |
|
Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide-coated titanium particles. | 2011 Jul |
|
DNA damage and alterations in expression of DNA damage responsive genes induced by TiO2 nanoparticles in human hepatoma HepG2 cells. | 2011 Sep |
|
TiO₂ nanoparticles induce dysfunction and activation of human endothelial cells. | 2012 Apr 16 |
|
Four types of inorganic nanoparticles stimulate the inflammatory reaction in brain microglia and damage neurons in vitro. | 2012 Oct 17 |
|
Titanium dioxide nanoparticles increase inflammatory responses in vascular endothelial cells. | 2013 Apr 5 |
|
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils. | 2013 Jul 31 |
|
Improving cytocompatibility of Co28Cr6Mo by TiO2 coating: gene expression study in human endothelial cells. | 2013 Sep 6 |
|
Effect of TiO₂ nanoparticles on the structure and activity of catalase. | 2014 Aug 5 |
|
Titanium dioxide nanoparticles promote arrhythmias via a direct interaction with rat cardiac tissue. | 2014 Dec 9 |
|
Genotoxicity of silver and titanium dioxide nanoparticles in bone marrow cells of rats in vivo. | 2014 Jan 6 |
|
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation. | 2014 Jul 1 |
|
Effect of pubertal nano-TiO2 exposure on testosterone synthesis and spermatogenesis in mice. | 2014 Mar |
|
Effects of titanium dioxide nanoparticles on lead bioconcentration and toxicity on thyroid endocrine system and neuronal development in zebrafish larvae. | 2015 Apr |
|
Release of titanium ions from an implant surface and their effect on cytokine production related to alveolar bone resorption. | 2015 Jan 2 |
|
Genome wide identification and expression profile in epithelial cells exposed to TiO₂ particles. | 2015 Mar |
|
Silver and titanium dioxide nanoparticles alter oxidative/inflammatory response and renin-angiotensin system in brain. | 2015 Nov |
|
Cyto- and genotoxic effects of metallic nanoparticles in untransformed human fibroblast. | 2015 Oct |
|
Titanium dioxide nanoparticles modulate the toxicological response to cadmium in the gills of Mytilus galloprovincialis. | 2015 Oct 30 |
|
TiO2 nanoparticle-induced neurotoxicity may be involved in dysfunction of glutamate metabolism and its receptor expression in mice. | 2016 Jun |
Sample Use Guides
Apply evenly 15 minutes before sun exposure. Reapply as needed or after towel drying, swimming, or perspiring. Children under 6 months of age, ask a doctor.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18503414
For the in vitro studies, the stratum corneum side of the skin was in contact with either the aqueous or oily commercial dispersion of microfine TiO2 (150 μl/cm^2). The dermis side was placed onto a tissue of cellulose soaked with isotonic phosphate buffered saline (PBS) of pH 7.4. Twenty-four hours after application of the dispersion, the PBS was removed from the skin with a dry paper towel. For the in vivo studies, 2 μl cm−2 of the commercial dispersions and the different formulations were applied onto the ventral side of the forearm of a healthy female volunteer. After 45 min, any dispersion or formulation that had not penetrated the skin was also removed with a paper towel. All penetration tests were performed in triplicate.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-171
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 178.3297
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
NCI_THESAURUS |
C461
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
DSLD |
1166 (Number of products:1)
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 38
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
199204
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 575
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
JECFA EVALUATION |
INS-171
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 352.20
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 175.210
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/05/262
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
EPA PESTICIDE CODE |
NOT YET ASSIGNED
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 576
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 352.10
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
142401
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 577
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12611MIG
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
869
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
C61975
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
C009495
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
DB09536
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
DTXSID3021352
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
1667585
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
4237
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
1317-80-2
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
ALTERNATIVE | |||
|
162651
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
46748
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
13463-67-7
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
38323
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
15FIX9V2JP
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
TITANIUM DIOXIDE
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
32234
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
134438
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
236-675-5
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
15FIX9V2JP
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
1344-29-2
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
ALTERNATIVE | |||
|
m10898
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000092217
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201136
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
215-282-2
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
ALTERNATIVE | |||
|
15204
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)